The Role of Shame in Schizophrenia Delusion by Borrelli, Davide Fausto, Ottoni, Rebecca, Maffei, Simone

Adolescent Social Functioning Deficits in Association With Adoptive Family Functioning and Genetic Risk for Schizophrenia Spectrum Disorders by Tikkanen Ville, Siira Virva, Wahlberg Karl-Erik, Helinä, Hakko, Myllyaho Toni, Läksy Kristian, Roisko Riikka

Sodium benzoate treatment linked to increased glutathione levels and improved positive and negative symptoms, global function, and quality of life in patients with clozapine-resist... by Lin, Chieh-Hsin, Lane, Hsien-Yuan

Integrating Self-management Support into Care - An Engaging Evidence-Based Option for Thriving with Schizophrenia by Strong, Susan, Letts, Lori, Gillespie, Alycia

Double-blind, randomized, placebo-controlled pilot clinical trial with gamma-band transcranial alternating current stimulation for the treatment of schizophrenia refractory auditor... by Wang, Xiaojuan, Zhang, Xiaochen, Chang, Yuan, Liao, Jingmeng, Liu, Shuang, Ming, Dong

Failing to Gain: Another Explanation of Cognitive Change in Schizophrenia and Other Psychoses in the Decade Following the First Episode/Further Analysis of Cognitive Change in Schi... by Panayiotou, Anita, Wood, Stephen, Stainton, Alexandra, Van Rheenen, Tamsyn, Allott, Kelly, Pantelis, Christos, Zanelli, Jolanta, Mollon, Josephine, Sandin, Sven, Reichenberg, Abraham

Transforming Schizophrenia Care in Ontario: A Collaborative Multi-Agency Partnership Approach to Enhancing Quality and Responsiveness Through An Integrated Care Model by Kipping, Sarah, McQuaid, Bethany

S203. EFFECT OF LONG-ACTING INJECTIONS OF PALIPERIDONE PALMITATE ON CLINICAL AND FUNCTIONAL OUTCOMES IN PATIENTS WITH SCHIZOPHRENIA BASED ON ILLNESS DURATION by Kim, Seoyoung, Youn Kim, Su, Jung Koh, Min, Jee Choi, Gum, Kim, Euitae

Single-Session Dance/Movement Therapy for Thought and Behavioral Dysfunction Associated With Schizophrenia by Biondo Jacelyn, Gerber, Nancy, Bradt Joke, Du, Wei, Goodill Sherry

Randomized, double-blind, sham-controlled trial to evaluate the efficacy and tolerability of electroconvulsive therapy in patients with clozapine-resistant schizophrenia by Melzer-Ribeiro, D.L., Napolitano, I.C., Leite, S.A., Alencar de Souza, J.A., Vizzotto, A.D.B., Di Sarno, E.S., Fortes, M., Gomes, M.L., de Oliveira, G.M., Avrichir, B.S., Talib, L.L., Correll, C.U., Elkis, H.

N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis by Conus, Philippe, Seidman, Larry J, Fournier, Margot, Xin, Lijing, Cleusix, Martine, Baumann, Philipp S, Ferrari, Carina, Cousins, Ann, Alameda, Luis, Gholam-Rezaee, Mehdi, Golay, Philippe, Jenni, Raoul, Woo, T -U Wilson, Keshavan, Matcheri S, Eap, Chin B, Wojcik, Joanne, Cuenod, Michel, Buclin, Thierry, Gruetter, Rolf, Do, Kim Q

Transcriptomic and Neurotransmitter Insights Into Gray Matter Volume Changes From 1 Hz rTMS in Treating Schizophrenia With Auditory Verbal Hallucinations by Xie, Yuanjun, Li, Chenxi, Guan, Muzhen, Zhang, Tian, Ma, Chaozong, Wang, Lingling, Li, Xinxin, Li, Yijun, Wang, Zhongheng, Wang, Huaning, Fang, Peng

Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology by Howes, Oliver D, McCutcheon, Rob, Agid, Ofer, de Bartolomeis, Andrea, van Beveren, Nico J.M, Birnbaum, Michael L, Bloomfield, Michael A.P, Bressan, Rodrigo A, Buchanan, Robert W, Carpenter, William T, Castle, David J, Citrome, Leslie, Daskalakis, Zafiris J, Davidson, Michael, Drake, Richard J, Dursun, Serdar, Ebdrup, Bjørn H, Elkis, Helio, Falkai, Peter, Fleischacker, W. Wolfgang, Gadelha, Ary, Gaughran, Fiona, Glenthøj, Birte Y, Graff-Guerrero, Ariel, Hallak, Jaime E.C, Honer, William G, Kennedy, James, Kinon, Bruce J, Lawrie, Stephen M, Lee, Jimmy, Leweke, F. Markus, MacCabe, James H, McNabb, Carolyn B, Meltzer, Herbert, Möller, Hans-Jürgen, Nakajima, Shinchiro, Pantelis, Christos, Reis Marques, Tiago, Remington, Gary, Rossell, Susan L, Russell, Bruce R, Siu, Cynthia O, Suzuki, Takefumi, Sommer, Iris E, Taylor, David, Thomas, Neil, Üçok, Alp, Umbricht, Daniel, Walters, James T.R, Kane, John, Correll, Christoph U

Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations by Müller, Norbert

Adjunctive semaglutide improves metabolic outcomes in patients with schizophrenia

Probiotic Formulation for Patients With Bipolar or Schizophrenia Spectrum Disorder: A Double-Blind, Randomized Placebo-Controlled Trial by Borkent, Jenny, Ioannou, Magdalini, Neijzen, Dorien, Haarman, Bartholomeus C M, Sommer, Iris E C

Emerging Neurobiological and Therapeutic Insights into Schizophrenia: A Comprehensive Review by Oatu, Anamaria, Capatina, Tudor-Florentin, Mandras, Iulia-Cristina, Comsa, Antonia-Lucia, Trifu, Simona, Pietreanu, Arina-Cipriana

Genetic Association Between NRXN3 Variants (rs12879016 & rs2270964) and Risk of Schizophrenia (SCZ) by Abdulmajeed Saleh Alzahrani, Wael Salah Alhazmi, Dandini, Mohammad Talal, Maher Mohammed Alsubhi, Mohammed Ali Mohammed Alghamdi, Rayid Shabib Mofareh Alotaibi, Marzouq Mohsen Alnefaie, Faris Khader Hasan Alhassani, Fahad Mansour Alhulayfi, Mutlaq Dakhel Fawaz Almalki

F230. COMPARISON OF PALIPERIDONE PALMITATE 3-MONTH AND PALIPERIDONE PALMITATE 1-MONTH FORMULATION FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A PHASE 3 NON-INFERIORITY STUDY by Mathews, Maju, Gopal, Srihari, Singh, Arun, Gogate, Jagadish, Kim, Edward, Pungor, Katalin

Effect of computerized cognitive training on P300 ERP impairments in Indian patients with schizophrenia by Singh, Jaskirat, Singh, Sukhwinder, Gupta, Savita, Kaur, Navneet